Research programme: small molecules - IM Therapeutics

Drug Profile

Research programme: small molecules - IM Therapeutics

Alternative Names: IMT 002; Methyldopa D-enantiomer

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Colorado at Denver
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus
  • Research Autoimmune disorders

Most Recent Events

  • 21 Dec 2017 IM Therapeutics plans a clinical trial of IMT 002 for type 1 diabetes mellitus in 2018
  • 06 Dec 2017 IM Therapeutics licenses worldwide rights to methyldopa and D enantiomer of methyldopa from the University of Colorado
  • 06 Dec 2017 IM Therapeutics has patent protection for Methyldopa and D enantiomer of methyldopa (IMT 002) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top